within Pharmacolibrary.Drugs.ATC.L;

model L01XX29
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 18 / 1000000,
    adminCount     = 1,
    Vd             = 0.0054,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Denileukin diftitox is a recombinant fusion protein composed of interleukin-2 and diphtheria toxin fragments. It binds to the high-affinity interleukin-2 (IL-2) receptor, resulting in selective cytotoxicity against malignant cells expressing this receptor. It was previously approved for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), but its use has been discontinued and is not currently approved or marketed.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults (both sexes) with cutaneous T-cell lymphoma, as peer-reviewed sources don't provide explicit compartmental PK model parameters.</p><h4>References</h4><ol><li><p>Kawai, H, et al., &amp; Tobinai, K (2021). Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. <i>Cancer science</i> 112(6) 2426–2435. DOI:<a href=&quot;https://doi.org/10.1111/cas.14906&quot;>10.1111/cas.14906</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33792128/&quot;>https://pubmed.ncbi.nlm.nih.gov/33792128</a></p></li><li><p>Ohmachi, K, et al., &amp; Nakanishi, T (2018). E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study. <i>Cancer science</i> 109(3) 794–802. DOI:<a href=&quot;https://doi.org/10.1111/cas.13513&quot;>10.1111/cas.13513</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29363235/&quot;>https://pubmed.ncbi.nlm.nih.gov/29363235</a></p></li><li><p>LeMaistre, CF, et al., &amp; Nichols, JC (1998). Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. <i>Blood</i> 91(2) 399–405. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9427692/&quot;>https://pubmed.ncbi.nlm.nih.gov/9427692</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX29;
